Skip to main content
. 2022 Aug 19;40(40):5752–5756. doi: 10.1016/j.vaccine.2022.08.031

Table 1.

Characteristics of tested HCP

Characteristic

N (%)
(n = 739)
Age, years (n = 714)
< 40 207 (29.0%)
40–59 435 (60.9%)
> 60 72 (10.1%)
Gender (n = 739)
male 238 (32.2%)
female 501 (67.8%)
Comorbidities1 (n = 498) 118 (23.7%)
Immunosupressive drugs (n = 511) 19 (3.7%)
BMI (n = 467)
< 20 32 (6.9%)
20–25 188 (40.2%)
> 25–30 167 (35.8%)
> 30 80 (17.1%)
Smoking (n = 510)
yes 167 (32.7%)
no 343 (67.3%)
Regular physical exercise (n = 513)
yes 111 (21.6%)
no 402 (78.4%)
SARS-CoV-2 infection2 (n = 739) 72 (9.7 %)
before vaccination 37
before 1st sampling3 1 3
before 2nd sampling4 3
before 3rd sampling5 19
Mild side effects post-vaccination (n = 510) 269 (52.7%)

n: the number of participants who answered this question; HCP: healthcare personnel; BMI: body mass index; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; RT-PCR: real-time polymerase chain reaction.

1

Co-morbidities included diabetes mellitus (26 HCP), autoimmune disorder (44 HCP), and other (57 HCP).

2

confirmed by RT-PCR.

3

after 2nd vaccine dose.

4

after first sampling and before third vaccine dose.

5

after second sampling and before third vaccine dose.